Related Experiment Video
Updated: Aug 7, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Cytochrome P450 3A: genetic polymorphisms and inter-ethnic differences
1Drug Metabolism, Cancer and Aging Research Lab, Department of Pharmacology, University College of Pharmaceutical Sciences, Kakatiya University, Warangal, Andhra Pradesh, India. dr_krishna@rediffmail.com
Methods and Findings in Experimental and Clinical Pharmacology
|November 8, 2005
Summary
Genetic variations in drug metabolism enzymes, particularly cytochrome P450 (CYP3A), differ between ethnic populations. This review explores ethnic variations and genetic polymorphism in CYP3A-mediated drug metabolism.
Area of Science:
- Pharmacogenomics
- Drug Metabolism
- Biochemistry
Background:
- Ethnicity influences drug response due to genetic variations in drug-metabolizing enzymes.
- Cytochrome P450 enzymes, especially CYP3A, are crucial for metabolizing a large proportion of prescribed drugs.
- Inter-ethnic differences in CYP3A activity and metabolism are well-documented.
Purpose of the Study:
- To review genetic polymorphism and ethnic variations in CYP3A-mediated oxidative drug metabolism.
- To highlight the impact of ethnicity on drug metabolism and response.
Main Methods:
- Literature review focusing on genetic polymorphism.
- Analysis of studies reporting ethnic variations in CYP3A activity.
- Examination of CYP3A-mediated drug metabolism pathways.
Main Results:
- Frequencies of genetic polymorphisms in drug-metabolizing enzymes vary significantly across different populations.
- Distinct CYP3A variants are observed in different ethnic groups, affecting enzyme activity.
- Inter-ethnic variability in CYP3A-mediated drug metabolism contributes to differences in drug response.
Conclusions:
- Genetic polymorphism and ethnic variations in CYP3A are key factors in interindividual differences in drug metabolism.
- Understanding these variations is essential for personalized medicine and optimizing drug therapy across diverse populations.
Related Concept Videos
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...